OSU-03012 sensitizes breast cancers to lapatinib-induced cell killing: A role for Nck1 but not Nck2

BMC Cancer

Volumn 13, Issue , 2013, Pages

  West, N Winston ^a   Garcia Vargas, Aileen ^b   Chalfant, Charles E ^b,c,d   Park, Margaret A ^b  

^a UNIVERSITY OF RICHMOND   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Breast cancer; Combination therapy; EIF2 alpha; Lapatinib; Nck

Indexed keywords

2 AMINO N [4 [5 (2 PHENANTHRENYL) 3 TRIFLUOROMETHYL 1H PYRAZOL 1 YL]PHENYL]ACETAMIDE; ADAPTOR PROTEIN; ALANINE; CELECOXIB; INITIATION FACTOR 2ALPHA; LAPATINIB; MUTANT PROTEIN; PROTEIN KINASE R; PROTEIN NCK1; PROTEIN NCK2; PROTEIN PERK; SERINE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; NCK PROTEIN; NCK2 PROTEIN, HUMAN; ONCOPROTEIN; PYRAZOLE DERIVATIVE; QUINAZOLINE DERIVATIVE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; SULFONAMIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CELL KILLING; CELL SURVIVAL; CELL VIABILITY; CHEMOSENSITIZATION; CONTROLLED STUDY; CYTOSTASIS; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG INTERACTION; ENZYME INHIBITION; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UPREGULATION; APOPTOSIS; BREAST TUMOR; DRUG EFFECTS; DRUG POTENTIATION; DRUG RESISTANCE; FEMALE; GENETIC TRANSFECTION; IMMUNOPRECIPITATION; METABOLISM; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; WESTERN BLOTTING;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HUMANS; IMMUNOPRECIPITATION; ONCOGENE PROTEINS; PYRAZOLES; QUINAZOLINES; SIGNAL TRANSDUCTION; SULFONAMIDES; TRANSFECTION;

EID: 84878006006     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-13-256     Document Type: Article

References (40)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62(1):10-29. 10.3322/caac.20138, 22237781.
2. Griffiths CL, Olin JL. Triple negative breast cancer: a brief review of its characteristics and treatment options. J Pharm Pract 2012, 25(3):319-323. 10.1177/0897190012442062, 22551559.
3. De Mattos-Arruda L, Cortes J. Advances in first-line treatment for patients with HER-2+ metastatic breast cancer. Oncologist 2012, 17(5):631-644. 10.1634/theoncologist.2011-0187, 3360903, 22523199.
4. Mukai H. Treatment strategy for HER2-positive breast cancer. Int J Clin Oncol 2010, 15(4):335-340. 10.1007/s10147-010-0107-0, 20632056.
5. Sorkin A, Goh LK. Endocytosis and intracellular trafficking of ErbBs. Exp Cell Res 2009, 315(4):683-696. 10.1016/j.yexcr.2008.07.029, 19278030.
6. Burgess AW. EGFR family: Structure physiology signalling and therapeutic targets. Growth Factors 2008, 26(5):263-274. 10.1080/08977190802312844, 18800267.
7. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EWT, Chang F, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007, 1773(8):1263-1284. 10.1016/j.bbamcr.2006.10.001, 2696318, 17126425.
8. Markman B, Dienstmann R, Tabernero J. Targeting the PI3K/Akt/mTOR Pathway - Beyond Rapalogs. Oncotarget 2010, 1(7):530-543. 3248125, 21317449.
9. Blackwell KL, Pegram MD, Tan-Chiu E, Schwartzberg LS, Arbushites MC, Maltzman JD, et al. Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Ann Oncol 2009, 20(6):1026-1031. 10.1093/annonc/mdn759, 19179558.
10. Lin NU, Diéras V, Paul D, Lossignol D, Christodoulou C, Stemmler HJ, et al. Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer. Clin Cancer Res 2009, 15(4):1452-1459. 10.1158/1078-0432.CCR-08-1080, 19228746.
11. Chen ST, Thomas S, Gaffney KJ, Louie SG, Petasis NA, Schonthal AH. Cytotoxic effects of celecoxib on raji lymphoma cells correlate with aggravated endoplasmic reticulum stress but not with inhibition of cyclooxygenase-2. Leuk Res 2010, 34(2):250-253. 10.1016/j.leukres.2009.09.028, 19833390.
12. Wang YC, Kulp SK, Wang D, Yang CC, Sargeant AM, Hung JH, et al. Targeting endoplasmic reticulum stress and akt with OSU-03012 and gefitinib or erlotinib to overcome resistance to epidermal growth factor receptor inhibitors. Cancer Res 2008, 68(8):2820-2830. 10.1158/0008-5472.CAN-07-1336, 18413750.
13. Park MA, Curiel DT, Koumenis C, Graf M, Chen CS, Fisher PB, et al. PERK-dependent regulation of HSP70 expression and the regulation of autophagy. Autophagy 2008, 4(3):364-367.
14. Yacoub A, Park MA, Hanna D, Hong Y, Mitchell C, Pandya AP, et al. OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells. Mol Pharmacol 2006, 70(2):589-603. 10.1124/mol.106.025007, 16622074.
15. Muaddi H, Majumder M, Peidis P, Papadakis AI, Holcik M, Scheuner D, et al. Phosphorylation of eIF2α at Serine 51 Is an Important Determinant of Cell Survival and Adaptation to Glucose Deficiency. Mol Biol Cell 2010, 21(18):3220-3231. 10.1091/mbc.E10-01-0023, 2938387, 20660158.
16. Teske BF, Wek SA, Bunpo P, Cundiff JK, McClintick JN, Anthony TG, et al. The eIF2 kinase PERK and the integrated stress response facilitate activation of ATF6 during endoplasmic reticulum stress. Mol Biol Cell 2011, 22(22):4390-4405. 10.1091/mbc.E11-06-0510, 3216664, 21917591.
17. Booth L, Cruickshanks N, Ridder T, Chen CS, Grant S, Dent P. OSU-03012 interacts with lapatinib to kill brain cancer cells. Cancer Biol Ther 2012, 13(14):1501-1511. PMID: 22990204, 10.4161/cbt.22275, 22990204.
18. Latreille M, Larose L. Nck in a Complex Containing the Catalytic Subunit of Protein Phosphatase 1 Regulates Eukaryotic Initiation Factor 2α Signaling and Cell Survival to Endoplasmic Reticulum Stress. J Biol Chem 2006, 281(36):26633-26644. 10.1074/jbc.M513556200, 16835242.
19. Kebache S, Cardin E, Nguyên DT, Chevet E, Larose L. Nck-1 antagonizes the endoplasmic reticulum stress-induced inhibition of translation. J Biol Chem 2004, 279(10):9662-9671. 10.1074/jbc.M310535200, 14676213.
20. Harding HP, Zeng H, Zhang Y, Jungries R, Chung P, Plesken H, et al. Diabetes mellitus and exocrine pancreatic dysfunction in perk-/- mice reveals a role for translational control in secretory cell survival. Mol Cell 2001, 7(6):1153-1163. 10.1016/S1097-2765(01)00264-7, 11430819.
21. Guan S, Fan J, Han A, Chen M, Woodley DT, Li W. Non-compensating roles between Nckalpha and Nckbeta in PDGF-BB signaling to promote human dermal fibroblast migration. J Invest Dermatol 2009, 129(8):1909-1920. 10.1038/jid.2008.457, 19242519.
22. Yacoub A, Mitchell C, Hong Y, Gopalkrishnan RV, Su ZZ, Gupta P, et al. MDA-7 regulates cell growth and radiosensitivity in vitro of primary (non-established) human glioma cells. Cancer Biol Ther 2004, 3(8):739-751. 10.4161/cbt.3.8.968, 15197348.
23. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984, 22:27-55.
24. Peng X, Jhaveri P, Hussain-Hakimjee EA, Mehta RG. Overexpression of ER and VDR is not sufficient to make ER-negative MDA-MB-231 breast cancer cells responsive to 1 alpha-hydroxyvitamin D5. Carcinogenesis 2007, 28(5):1000-1007.
25. Clinchy B, Gazdar A, Rabinovsky R, Yefenof E, Gordon B, Vitetta ES. The growth and metastasis of human, HER-2/neu-overexpressing tumor cell lines in male SCID mice. Breast Cancer Res Treat 2000, 61(3):217-228. 10.1023/A:1006494001861, 10965998.
26. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006, 10:515-527. 10.1016/j.ccr.2006.10.008, 2730521, 17157791.
27. Sanz-Pamplona R, Aragüés R, Driouch K, Martín B, Oliva B, Gil M, et al. Expression of Endoplasmic Reticulum Stress Proteins Is a Candidate Marker of Brain Metastasis in both ErbB-2+ and ErbB-2- Primary Breast Tumors. Am J Pathol 2011, 179(2):564-579. 10.1016/j.ajpath.2011.04.037, 3157240, 21708117.
28. Sequeira SJ, Ranganathan AC, Adam AP, Iglesias BV, Farias EF, Aguirre-Ghiso JA. Inhibition of proliferation by PERK regulates mammary acinar morphogenesis and tumor formation. PLoS One 2007, 2(7):e615. 10.1371/journal.pone.0000615, 1910610, 17637831.
29. Noh EM, Lee YR, Chay KO, Chung EY, Jung SH, Kim JS, Youn HJ. Estrogen receptor α induces down-regulation of PTEN through PI3-kinase activation in breast cancer cells. Mol Med Rep. 2011, 4(2):215-219. PMID: 21468554.
30. Gong C, Yao Y, Wang Y, Liu B, Wu W, Chen J, Su F, Yao H, Song E. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer. J Biol Chem 2011 May 27, 286(21):19127-19137. PMID:21471222.
31. Callans LS, Naama H, Khandelwal M, Plotkin R, Jardines L. Raf-1 protein expression in human breast cancer cells. Ann Surg Oncol 1995 Jan, 2(1):38-42.
32. Kataoka Y, Mukohara T, Shimada H, Saijo N, Hirai M, Minami H. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines. Ann Oncol 2010 Feb, 21(2):255-262.
33. Mounir Z, Krishnamoorthy JL, Robertson GP, Scheuner D, Kaufman RJ, Georgescu MM, et al. Tumor Suppression by PTEN Requires the Activation of the PKR-eIF2{alpha} Phosphorylation Pathway. Sci Signal 2009, 2(102):85.
34. O'Loghlen A, Pérez-Morgado MI, Salinas M, Martín ME. Reversible inhibition of the protein phosphatase 1 by hydrogen peroxide: Potential regulation of eIF2α phosphorylation in differentiated PC12 cells. Arch Biochem Biophys 2003, 417(2):194-202. 10.1016/S0003-9861(03)00368-0, 12941301.
35. Kim SH, Forman AP, Mathews MB, Gunnery S. Human breast cancer cells contain elevated levels and activity of the protein kinase, PKR. Oncogene. 2000, 19(27):3086-94. 10.1038/sj.onc.1203632, 10871861.
36. Eden S, Rohatgi R, Podtelejnikov AV, Mann M, Kirschner MW. Mechanism of regulation of WAVE1-induced actin nucleation by Rac1 and Nck. Nature 2002, 418(6899):790-793. 10.1038/nature00859, 12181570.
37. Huang M, Anand S, Murphy EA, Desgrosellier JS, Stupack DG, Shattil SJ, Schlaepfer DD, Cheresh DA. EGFR-dependent pancreatic carcinoma cell metastasis through Rap1 activation. Oncogene 2012, 31(22):2783-2793. 10.1038/onc.2011.450, 21963850.
38. De Benedetti A, Graff JR. eIF-4E expression and its role in malignancies and metastases. Oncogene 2004, 23(18):3189-3199. 10.1038/sj.onc.1207545, 15094768.
39. Ranganathan AC, Zhang L, Adam AP, Aguirre-Ghiso JA. Functional coupling of p38-induced Upregulation of BiP and activation of RNA-dependent protein kinase-like endoplasmic reticulum kinase to drug resistance of dormant carcinoma cells. Cancer Res 2006, 66:1702-1711. 10.1158/0008-5472.CAN-05-3092, 2515937, 16452230.
40. Sharma SV, Settleman J. Exploiting the balance between life and death: Targeted cancer therapy and " oncogenic shock" Biochem. Pharmacol 2010, 80(5):666-673.